Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Key Terms

molecular subtyping medical

Molecular subtyping is the classification of a disease or condition based on its underlying genes, proteins, or other molecular features rather than just visible symptoms. For investors, it matters because these finer categories can determine which patients respond to a drug or test, shaping market size, pricing, regulatory paths and the odds of commercial success—think of it like splitting a general product into precise versions that fit different customer needs.

neoadjuvant chemo-immunotherapy medical

Neoadjuvant chemo-immunotherapy is a treatment approach that combines chemotherapy and immunotherapy given before the main intervention (often surgery) to shrink a tumor and boost the patient’s immune response against cancer. For investors, success in this setting can speed regulatory approval, expand a drug’s use, and increase commercial value because it often indicates a therapy works both to reduce disease burden and to train the immune system—like softening a stubborn knot and teaching the body’s defenses how to spot it, improving overall outcomes.

biomarker medical

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

phase 2 trials medical

Phase 2 trials are mid-stage clinical studies that test whether a new treatment works in patients and continue to monitor safety, usually with a larger but still limited group than early safety tests. Think of it as a focused dress rehearsal that checks effectiveness and side effects in the real audience; positive results reduce the risk and raise the value of a drug program for investors, while failures or concerning side effects can sharply lower expectations.

genomic classifier medical

A genomic classifier is a medical test that reads patterns in a person’s genes to predict how a disease will behave or which treatments are most likely to work. For investors, it matters because these tests can change which drugs are used, speed up clinical decisions, influence health care costs and reimbursement, and create market opportunities or risks depending on clinical value, regulatory approval and adoption — like a weather forecast helping planners decide which storm preparations to make.

real‑world data technical

Real-world data are health and usage information collected outside of formal clinical trials, such as electronic medical records, insurance claims, patient registries, wearable devices, and surveys. For investors, it matters because this “everyday” evidence shows how a drug, device, or service performs in routine practice—like a test drive compared with a lab test—helping assess market uptake, ongoing safety, pricing power, and regulatory or reimbursement prospects.

pet imaging medical

PET imaging is a noninvasive medical scan that works like a molecular camera, using tiny radioactive tracers to reveal biological activity inside the body—for example metabolism, blood flow, or the presence of specific proteins. It matters to investors because PET results guide diagnosis, show whether a drug reaches its intended target and how patients respond, and therefore affect clinical trial success, regulatory approval, reimbursement decisions and demand for scanners, tracers and related services.

tgf-β medical

TGF-β (transforming growth factor beta) is a naturally occurring signaling protein that cells use to control growth, repair and immune responses; think of it as a traffic light that can either slow, stop or redirect cellular behavior depending on the situation. It matters to investors because drugs that block or boost TGF-β pathways are key candidates for treating cancer, fibrosis and autoimmune conditions, and trial outcomes or regulatory news about these therapies can greatly affect a biotech company’s value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in bladder cancer and feature national-scale real‑world data analyses in prostate cancer that demonstrate how Decipher Prostate informs treatment decisions. Additional real‑world data from the Decipher Genomics Research for Intelligent Discovery (GRID) research tool continues to fuel the flywheel of evidence in urologic cancers through ongoing research studies.

“These studies underscore the power of Veracyte’s Diagnostics Platform to generate clinically meaningful evidence at scale,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “With more than a decade of data in our Decipher GRID tool, we are accelerating research to drive new discoveries that help clinicians better personalize care and improve outcomes for patients.”

At this year’s meeting, during Bladder Cancer Awareness month in May, several studies will highlight the clinical relevance of molecular subtyping in bladder cancer using the Decipher Bladder test, including its role in guiding treatment decisions and predicting outcomes. Key presentations include:

Title:	Molecular Characterization and a Showcase Clinical Study on Treatment De-escalation for Luminal Favorable Muscle-Invasive Bladder Cancer
Presenter:	Melissa Moran, DO, Rutgers Robert Wood Johnson University Hospital
Format:	Poster
Abstract #:	IP35-15
Date/Time:	Saturday, May 16, 2026, 9:30 – 11:30 AM ET
Location:	147A
Title:	Non-luminal molecular subtypes demonstrate highest complete response rates after neoadjuvant chemo-immunotherapy for Muscle-Invasive Bladder Cancer (Biomarker analyses from NURE-combo & BLASST-01 phase 2 trials)
Presenter:	Joep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands
Format:	Poster
Abstract #:	IP47-06
Date/Time:	Saturday, May 16, 2026, 3:30 - 5:30 PM ET
Location:	147A
Title:	Non-Luminal Subtype is Associated with Worse Overall Survival in High-Risk Non-Muscle Invasive Bladder Cancer Patients - Biomarker Results from The Bladder Cancer Prognosis Programme
Presenter:	Joep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands
Format:	Poster
Abstract #:	IP47-07
Date/Time:	Saturday, May 16, 2026, 3:30 - 5:30 PM ET
Location:	147A
Title:	Examining the impact of TGF-β activity on fibroblast infiltration and immune exclusion in muscle-invasive bladder cancer
Presenter:	Shilpa Gupta, M.D., Cleveland Clinic Foundation
Format:	Podium presentation
Abstract #:	PD15-10
Date/Time:	Saturday, May 16, 2026, 4:42 - 4:50 PM ET
Location:	206

Together, these studies demonstrate how molecular subtyping can help refine risk stratification, identify patient subsets with differing clinical outcomes, and deepen understanding of tumor biology.

“These data suggest that molecular subtyping using Decipher Bladder may help identify patients who are more likely to achieve downstaging and complete responses to neoadjuvant chemo-immunotherapy,” said Shilpa Gupta, M.D., GU Oncologist, Cleveland Clinic. “By better understanding tumor biology upfront, we have the potential to more precisely select therapies and, ultimately, improve outcomes while avoiding unnecessary treatment for patients with muscle-invasive bladder cancer.”

Unlocking Insights with Real-World Evidence from Decipher Prostate and the GRID Database

Large‑scale analyses using Decipher genomic data alongside real‑world clinical datasets provide insights into how prostate cancer management is being shaped across diverse patient populations, helping clinicians more confidently tailor treatment decisions. These efforts also support ongoing research to deepen understanding of prostate cancer biology and inform personalized care. Key presentations include:

Title:	Association of Biopsy-Based Genomic Classifier and Initial Treatment for Prostate Cancer: Results from a National Clinical–Genomic Linkage
Presenter:	Michael Leapman, M.D., Department of Urology, Yale School of Medicine
Format:	Poster
Abstract #:	IP31-20
Date/Time:	Saturday, May 16, 2026, 9:30 - 11:30 AM ET
Location:	145AB
Title:	Genomic Classifier Results and Use of Post-Prostatectomy Treatment Among a National Cohort of Patients with Prostate Cancer
Presenter:	Michael Leapman, M.D., Department of Urology, Yale School of Medicine
Format:	Poster
Abstract #:	IP62-22
Date/Time:	Sunday, May 17, 2026, 1:00 - 3:00 PM ET
Location:	146A
Title:	Correlative analysis of the expression of two PET imaging targets, PSMA and ACP3, in a large radical prostatectomy cohort from the Decipher GRID registry
Presenter:	Mohammed Shahait, M.D., UCI Urology
Format:	Poster
Abstract #:	IP62-05
Date/Time:	Sunday, May 17, 2026, 1:00 - 3:00 PM ET
Location:	146A

“Decipher GRID enables analyses that were not previously possible,” said Dr. Michael Leapman Associate Professor of Urology, Yale School of Medicine. “Our findings suggest that genomic information from Decipher Prostate may help refine treatment decision-making and move care toward more precise, individualized management of prostate cancer.”

More information about Veracyte’s presence at AUA 2026 can be found at the company’s booth #3405 and on Veracyte’s website here.

About Decipher Prostate

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients. It is the only gene expression test to achieve “Level 1B” evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.

About Decipher Bladder

The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.

About Decipher GRID

The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More information about Decipher GRID can be found here.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to regarding the potential clinical utility, impact, and benefits of Veracyte’s Decipher Bladder and Prostate tests; how molecular subtyping can help inform treatment decisions, improve patient outcomes, or avoid unnecessary treatment for patients; the role of real‑world data and the Decipher Genomics Research for Intelligent Discovery (GRID) platform in advancing research or enabling new discoveries; and the potential impact of Veracyte’s diagnostic solutions.. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026 and our subsequent Quarterly Reports on Form 10-Q. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

*National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428470902/en/

Investors:
Kelly Gura
investors@veracyte.com

Media:
Molly Cornbleet
media@veracyte.com

Source: Veracyte, Inc.